1040 related articles for article (PubMed ID: 17727798)
1. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil.
Wu J; Lu Y; Lee A; Pan X; Yang X; Zhao X; Lee RJ
J Pharm Pharm Sci; 2007; 10(3):350-7. PubMed ID: 17727798
[TBL] [Abstract][Full Text] [Related]
2. [The in vitro cytotoxicity and in vivo toxicity of doxorubicin antiresistant stealth liposomes].
Wang JC; Liu XY; Lü WL; Lee HS; Goh BC; Zhang Q
Yao Xue Xue Bao; 2005 May; 40(5):475-80. PubMed ID: 16220797
[TBL] [Abstract][Full Text] [Related]
3. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Xu HB; Li L; Liu GQ
Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169
[TBL] [Abstract][Full Text] [Related]
4. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
Li X; Ding L; Xu Y; Wang Y; Ping Q
Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
[TBL] [Abstract][Full Text] [Related]
5. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells.
Kobayashi T; Ishida T; Okada Y; Ise S; Harashima H; Kiwada H
Int J Pharm; 2007 Feb; 329(1-2):94-102. PubMed ID: 16997518
[TBL] [Abstract][Full Text] [Related]
6. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
7. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.
Goren D; Horowitz AT; Tzemach D; Tarshish M; Zalipsky S; Gabizon A
Clin Cancer Res; 2000 May; 6(5):1949-57. PubMed ID: 10815920
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of intravenously administered stealth liposomal doxorubicin modulated with verapamil in rats.
Wang JC; Liu XY; Lu WL; Chang A; Zhang Q; Goh BC; Lee HS
Eur J Pharm Biopharm; 2006 Jan; 62(1):44-51. PubMed ID: 16126379
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of anticancer effects of newly synthesized dihydropyridine derivatives in comparison to verapamil and doxorubicin on T47D parental and resistant cell lines in vitro.
Bazargan L; Fouladdel S; Shafiee A; Amini M; Ghaffari SM; Azizi E
Cell Biol Toxicol; 2008 Apr; 24(2):165-74. PubMed ID: 17805981
[TBL] [Abstract][Full Text] [Related]
10. Targeted adriamycin delivery to MXT-B2 metastatic mammary carcinoma cells by transferrin liposomes: effect of adriamycin ADR-to-lipid ratio.
Lopez-Barcons LA; Polo D; Llorens A; Reig F; Fabra A
Oncol Rep; 2005 Nov; 14(5):1337-43. PubMed ID: 16211306
[TBL] [Abstract][Full Text] [Related]
11. Proanthocyanidin from grape seeds enhances doxorubicin-induced antitumor effect and reverses drug resistance in doxorubicin-resistant K562/DOX cells.
Zhang XY; Li WG; Wu YJ; Bai DC; Liu NF
Can J Physiol Pharmacol; 2005 Mar; 83(3):309-18. PubMed ID: 15870845
[TBL] [Abstract][Full Text] [Related]
12. In vitro cytotoxicity of Stealth liposomes co-encapsulating doxorubicin and verapamil on doxorubicin-resistant tumor cells.
Wang J; Goh B; Lu W; Zhang Q; Chang A; Liu XY; Tan TM; Lee H
Biol Pharm Bull; 2005 May; 28(5):822-8. PubMed ID: 15863886
[TBL] [Abstract][Full Text] [Related]
13. Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes.
Chiu SJ; Liu S; Perrotti D; Marcucci G; Lee RJ
J Control Release; 2006 May; 112(2):199-207. PubMed ID: 16564596
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
Wong HL; Bendayan R; Rauth AM; Wu XY
J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
[TBL] [Abstract][Full Text] [Related]
15. R-dl-verapamil downmodulates multidrug resistance of KBv200 cells to vincristine and doxorubicin.
Fang G; Yang YL; Li JS; Zhang ZX
Zhongguo Yao Li Xue Bao; 1999 Jul; 20(7):647-50. PubMed ID: 10678132
[TBL] [Abstract][Full Text] [Related]
16. Reduction of doxorubicin resistance in P-glycoprotein overexpressing cells by hybrid cell-penetrating and drug-binding peptide.
Zheng Z; Aojula H; Clarke D
J Drug Target; 2010 Jul; 18(6):477-87. PubMed ID: 20088680
[TBL] [Abstract][Full Text] [Related]
17. The synergistic reversal effect of multidrug resistance by quercetin and hyperthermia in doxorubicin-resistant human myelogenous leukemia cells.
Shen J; Zhang W; Wu J; Zhu Y
Int J Hyperthermia; 2008 Mar; 24(2):151-9. PubMed ID: 18283591
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Pgp activity and cell cycle-dependent chemosensitivity to doxorubicin in the multidrug-resistant LoVo human colon cancer cell line.
Toffoli G; Corona G; Gigante M; Boiocchi M
Eur J Cancer; 1996 Aug; 32A(9):1591-7. PubMed ID: 8911123
[TBL] [Abstract][Full Text] [Related]
19. Reversal of multidrug resistance in leukemia cells using a transferrin-modified nanomicelle encapsulating both doxorubicin and psoralen.
Wang HW; Ma KL; Liu H; Zhou JY
Aging (Albany NY); 2020 Apr; 12(7):6018-6029. PubMed ID: 32259795
[TBL] [Abstract][Full Text] [Related]
20. Co-delivery of doxorubicin and P-gp inhibitor by a reduction-sensitive liposome to overcome multidrug resistance, enhance anti-tumor efficiency and reduce toxicity.
Tang J; Zhang L; Gao H; Liu Y; Zhang Q; Ran R; Zhang Z; He Q
Drug Deliv; 2016 May; 23(4):1130-43. PubMed ID: 25491241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
